BridgeBio Pharma, Inc.
BBIO · XNASCIK 1743881fmd_00HJPW3HP906QPBTC52Z6ZY4N3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 35 periods
Latest annual · FY2025
Millions- Total revenues
- 502
- Gross profit
- 481
- Operating income
- (523)
- Net income
- (733)
- Free cash flow
- (447)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 353
- Gross profit
- 333
- Operating income
- (12)
- Net income
- (57)
- Free cash flow
- (44)
Daily close · BBIOIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions79.51 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +86.3%
- Revenue, 5 yearsFY2020 to FY2025
- +127.4%
- Net income, 5 yearsFY2020 to FY2025
- n/m
BridgeBio Pharma, Inc. (BBIO) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $502.1 million | $221.9 million | +126.3% | 10-K 2026-02-24 · proof |
| Gross profit | $481.1 million | $218 million | +120.7% | 10-K 2026-02-24 · proof |
| Operating income | -$523.4 million | -$593 million | 10-K 2026-02-24 · proof | |
| Net income | -$732.9 million | -$543.3 million | 10-K 2026-02-24 · proof | |
| Cash from operating activities | -$445.9 million | -$520.7 million | 10-K 2026-02-24 · proof | |
| Free cash flow | -$447 million | -$521.7 million | 10-K 2026-02-24 · proof | |
| Total assets | $936 million | $919.3 million | +1.8% | 10-K 2026-02-24 · proof |
| Total liabilities | $3 billion | $2.4 billion | +26.7% | 10-K 2026-02-24 · proof |
| Cash and cash equivalents | $570.1 million | $681.1 million | -16.3% | 10-K 2026-02-24 · proof |
- What was BridgeBio Pharma, Inc. (BBIO)'s revenue in fiscal 2025?
- BridgeBio Pharma, Inc. (BBIO) reported revenue of $502.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $221.9 million the year before (+126.3%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was BridgeBio Pharma, Inc. (BBIO)'s gross profit in fiscal 2025?
- BridgeBio Pharma, Inc. (BBIO) reported gross profit of $481.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $218 million the year before (+120.7%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was BridgeBio Pharma, Inc. (BBIO)'s operating income in fiscal 2025?
- BridgeBio Pharma, Inc. (BBIO) reported operating income of -$523.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$593 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was BridgeBio Pharma, Inc. (BBIO)'s net income in fiscal 2025?
- BridgeBio Pharma, Inc. (BBIO) reported net income of -$732.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$543.3 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was BridgeBio Pharma, Inc. (BBIO)'s cash from operating activities in fiscal 2025?
- BridgeBio Pharma, Inc. (BBIO) reported cash from operating activities of -$445.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$520.7 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was BridgeBio Pharma, Inc. (BBIO)'s free cash flow in fiscal 2025?
- BridgeBio Pharma, Inc. (BBIO) reported free cash flow of -$447 million for fiscal 2025 (the year ended Dec 31, 2025), against -$521.7 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are BridgeBio Pharma, Inc. (BBIO)'s total assets?
- As of Dec 31, 2025, BridgeBio Pharma, Inc. (BBIO) reported total assets of $936 million, against $919.3 million a year earlier (+1.8%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are BridgeBio Pharma, Inc. (BBIO)'s total liabilities?
- As of Dec 31, 2025, BridgeBio Pharma, Inc. (BBIO) reported total liabilities of $3 billion, against $2.4 billion a year earlier (+26.7%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are BridgeBio Pharma, Inc. (BBIO)'s cash and cash equivalents?
- As of Dec 31, 2025, BridgeBio Pharma, Inc. (BBIO) reported cash and cash equivalents of $570.1 million, against $681.1 million a year earlier (-16.3%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:BBIO&period_type=annual&limit=5"Information only, not investment advice.